Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written signed and dated informed consent obtained.~* Male or female patients aged ≥ 18 years.~* A positive reversibility test~* Patients who experienced at least one severe exacerbation in the 12 months before entry (but not in the last month)~* Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free combination with long acting beta2 agonists (LABA) at a constant dose for two months before screening visit~* Not fully controlled asthmatics (which means partly controlled or/and uncontrolled patients according to GINA guidelines 2007) in the last month before screening visit~* Forced expiratory volume in the first second (FEV1) ≥ 60% of predicted for the patient normal value.~* Non smokers or ex-smokers~Exclusion Criteria:~* Pregnant or nursing (lactating) women. Women of child-bearing potential UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/mL or are using one or more of acceptable methods of contraception~* Body Mass Index (BMI) \> 34 kg/m2.~* Patient with lower respiratory tract infections affecting the patient's asthma within 30 days of the screening visit.~* Use of systemic steroids in the last month.~* Patients with other lung diseases such as COPD, cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder.~* Patients who have an uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease.~* Clinically relevant laboratory abnormalities~* Patients who have an abnormal QTcF interval value~* Intolerance or contra-indication to treatment with beta2-agonists and/or ICS or allergy to any component of the study treatments.~* Patients treated with slow-release corticosteroids in the 3 months prior to screening visit.~* Patients being treated with anti-IgE antibodies.~* Patients treated with LABA or ICS/LABA fixed combination in the 24h before screening visit~* Severe asthma exacerbation in the last month before screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beclometasone/formoterol (100/6 µg) (Type: EXPERIMENTAL): Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
- salbutamol (Type: ACTIVE_COMPARATOR): Ventolin : salbutamol sulphate 100 µg per metered dose

Based on this trial design, predict the completion outcome and termination type (if applicable).